Luqa Pharmaceuticals Acquires Arista, A China Medical Aesthetics In-Licensing Company

Luqa Pharma of Shanghai signed a definitive agreement to acquire Arista Pharma. Like Luqa, Arista in-licenses aesthetic products for China, including Aethoxysklerol®, an injected treatment for varicose veins that provides an alternative to surgery. Founded in 2010, Luqa is building a portfolio of aesthetic products, both OTC and prescription offerings, for the China market. Luqa did not disclose the transaction price for Arista.